Author(s):
M. R. Ghante, R. B. Tangade, S. D. Sawant, P. D. Kulkarni, V. K. Bhusari
Email(s):
mrghante@gmail.com
DOI:
10.52711/0974-360X.2022.00831 
Address:
M. R. Ghante1*, R. B. Tangade1, S. D. Sawant2, P. D. Kulkarni3 , V. K. Bhusari1
1Department of Pharmaceutical Quality Assurance, Smt. Kashibai Navale College of Pharmacy, Savitribai Phule Pune University, Pune, Maharashtra, India.
2Department of Pharmaceutical Chemistry, Smt. Kashibai Navale College of Pharmacy, Savitribai Phule Pune University, Pune, Maharashtra, India.
3Department of Quality Assurance Techniques, Gahlot Institute of Pharmacy, Koparkhaine, Navi Mumbai, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 11,
Year - 2022
ABSTRACT:
Background: From the literature survey it was found that stability indicating analytical methods have not been reported for evaluation of Ertugliflozin in drug substance (bulk or API) and on drug product. Objective: Developing and validating stability indicating RP-HPLC analytical method for the estimation of Ertugliflozin. Method: Current study develops a novel analytical method for separating drug from the degradation products that is formed under stress conditionsby utilizing methanol: water as mobile phase in the composition of 90:10 v/v using HiQ Sil C-18 (150×4.6)mm, 5.0µm column usingUV detection at 260 nm and flow rate of 0.7 mL/min. Results: Retention time for Ertugliflozin was observed to be 4.1 min. Ertugliflozin was exposed to stress conditions of hydrolysis (acid and alkali degradation), oxidation, photolysis and neutral decomposition. The developed method was validated taking into reference ICH guidelines. Conclusion: This method can be used routinely in pharmaceutical industries to analyse drugs in pharmaceutical dosage forms.
Cite this article:
M. R. Ghante, R. B. Tangade, S. D. Sawant, P. D. Kulkarni , V. K. Bhusari. Development and Validation of stability indicating RP-HPLC method for the estimation of Ertugliflozin by forced degradation studies. Research Journal of Pharmacy and Technology. 2022; 15(11):4945-9. doi: 10.52711/0974-360X.2022.00831
Cite(Electronic):
M. R. Ghante, R. B. Tangade, S. D. Sawant, P. D. Kulkarni , V. K. Bhusari. Development and Validation of stability indicating RP-HPLC method for the estimation of Ertugliflozin by forced degradation studies. Research Journal of Pharmacy and Technology. 2022; 15(11):4945-9. doi: 10.52711/0974-360X.2022.00831 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-11-16
REFERENCES:-
1. Miao Z. Nucci G. Amin N. Sharma R. Mascitti V. Tugnait M. Vaz A. et al. Pharmacokinetics, metabolism and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013; 41(2):445-456. doi.org/10.1124/dmd.112.049551
2. Cinti F. Moffa S. Impronta F. Cefalo C. Sun V. Sorice G. Mezza T. Giaccari A. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Design Development and Therapy. 2017; 11:2905-2919. doi.org/10.2147/dddt.s114932
3. https://www.drugbank.ca/drugs/DB11827 (Accessed Jan 08, 2022).
4. Nguyen VK, White Jr. Overview of Ertugliflozin. Clinical Diabetes: a Publication of the American Diabetes Association. 2019; 37(2):176-178. doi.org/10.2337/cd18-0097
5. Rao P. Rao A. Prasad S. A new stability indicating RP-HPLC method for simultaneous estimation of Ertugliflozin and Sitagliptin in bulk and pharmaceutical dosage form its validation as per ICH guidelines. Indo American Journal of Pharmaceutical Sciences. 2018; 05(04):2616-2627. doi/10.5281/zenodo.1220228.svg
6. Suneetha A. Mounika V. Sajid S. Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sitagliptin and Ertugliflozin in bulk and tablet dosage forms. Asian Journal of Pharmaceutical Analysis. 2020; 10(02):81-85. doi.org/10.5958/2231-5675.2020.00014.9
7. International Conference on Harmonization, Q2(R1): Validation of Analytical Procedures: Text and Methodology, Geneva (2005).
8. Singh S. Bakshi M. Guidance on Conduct of Stress Tests to Determine Inherent Stability of Drugs. 2000.
9. International Conference on Harmonization, Q1A(R2): Stability testing of new drug substances and products, Geneva (2003).